Valuation: Vaxart, Inc.

Market Cap 124M 109M 100M 92.37M 174M 11.97B 178M 1.2B 471M 5.86B 467M 456M 20.18B P/E 2026 *
-2.64x
P/E 2027 * -0.52x
Enterprise Value 124M 109M 100M 92.37M 174M 11.97B 178M 1.2B 471M 5.86B 467M 456M 20.18B EV / Sales 2026 *
0.62x
EV / Sales 2027 * 52.9x
Free-Float
98.36%
Yield 2026 *
-
Yield 2027 * -
1 day+0.03%
1 week-5.68%
Current month-14.88%
1 month-6.53%
3 months-31.33%
6 months-26.61%
Current year+48.67%
1 week 0.5
Extreme 0.5007
0.58
1 month 0.49
Extreme 0.488
0.65
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
10.33
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
22/05/26 Buy

Director

10,000 0.0041%
19/05/26 Tax

Chief Financial Officer

-31,395 0.0130%
23/04/26 Free

Director

236,200 0.0982%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-5.68%+16.86%-33.97% 124M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.49%-2.93%+38.17%+162.24% 23.37B
Weighted average by Cap. -2.80%-2.36%+39.54%+143.03%

Financials

2026 *2027 *
Net sales 200M 175M 162M 149M 281M 19.3B 287M 1.93B 760M 9.45B 753M 736M 32.55B 2.35M 2.05M 1.9M 1.75M 3.29M 226M 3.37M 22.65M 8.91M 111M 8.83M 8.63M 382M
Net income -24.4M -21.33M -19.68M -18.14M -34.19M -2.35B -34.95M -235M -92.52M -1.15B -91.65M -89.64M -3.96B -266M -233M -215M -198M -373M -25.63B -381M -2.57B -1.01B -12.55B -1B -978M -43.22B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
17/07/26 $0.5150 +0.03% 287,049
16/07/26 $0.5149 -2.86% 348,173
15/07/26 $0.5300 -3.64% 237,776
14/07/26 $0.5500 +1.47% 317,434
13/07/26 $0.5421 -0.72% 258,324
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5150USD
Average target price
3.333USD
Spread / Average Target
+547.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock